Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BeiGene In-Licenses TNF-based Immunotherapy in $126 Million Agreement

publication date: Feb 18, 2021

Beijing's BeiGene in-licensed greater China rights to novel tumor necrosis factor receptor 2 (TNFR2) antagonist antibodies from Boston Immune Technologies and Therapeutics (BITT) in an agreement worth up to $126 million. TNFR2 is selectively expressed on many tumor types and also on suppressive immune cells in the tumor microenvironment. BeiGene plans to test BITR2101, BITT’s lead TNFR2 antagonist antibody, as a single agent and in combination with tislelizumab, the company’s anti-PD-1 antibody. More details....

Stock Symbol: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital